WCLC 2023 Expert Perspectives

CE / CME

2023 World Conference on Lung Cancer: Expert Perspectives on Key Studies

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: November 17, 2023

Expiration: November 16, 2024

Matthew Gubens
Matthew Gubens, MD, MS, FASCO
Helena Yu
Helena Yu, MD

Activity

Progress
1
Course Completed

Introduction

In this module, Matthew Gubens, MD, MS, and Helena Yu, MD, discuss key findings in the management of lung cancer presented at the at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer (WCLC), including updates in advanced and early-stage non-small-cell lung cancer (NSCLC) and extensive-stage small-cell lung cancer (ES-SCLC).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with lung cancer do you provide care for in a typical month?

Which of the following findings was reported at WCLC 2023 for the phase III FLAURA2 study evaluating the combination of osimertinib plus platinum-based chemotherapy (CT) compared with the standard of care (SoC) of osimertinib alone in patients with newly diagnosed EGFR-mutated advanced NSCLC?

Which of the following tumor HER3 expression levels was associated with antitumor activity in the phase II HERTHENA-Lung01 study evaluating the HER3-targeted antibody–drug conjugate (ADC) patritumab deruxtecan in patients with EGFR-mutated advanced NSCLC after prior treatment with EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based CT?

Which of the following findings was reported at WCLC 2023 in a preliminary analysis of the phase II EVOKE-02 study evaluating the first-line combination of the TROP-2 ADC sacituzumab govitecan plus pembrolizumab in metastatic NSCLC?

In an exploratory subgroup analysis from the EMPOWER-Lung 1 and 3 studies, a survival benefit was reported for patients with newly diagnosed advanced NSCLC and baseline liver metastases with which of the following cemiplimab-based regimens compared with CT?